- Details
- Zachary Klaassen speaks with Neeraj Agarwal about the Phase III randomized MEVPRO-1 study examining mevrometostat in combination with enzalutamide for mCRPC patients previously treated with abiraterone acetate. Dr. Agarwal explains that EZH2, a key component of the Polycomb Repressive Complex II, functions by adding methyl groups to histone proteins, leading to gene silencing. The trial randomizes...
|
- Details
- Daniel Childs discusses real-world outcomes of lutetium-PSMA-617 treatment in prostate cancer patients with liver metastases, based on Mayo Clinic registry data. Dr. Childs presents findings showing that patients with liver metastases experience shorter overall survival (approximately 8.3 months), complete fewer treatment cycles, and demonstrate lower PSA response rates compared to those without l...
|
- Details
- Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences i...
|
- Details
- Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion highlights how lutetium-PSMA therapy can be safely administered following radium treatment, with outcomes consistent across different treatment sequences and timing intervals. They examine how these...
|
- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Noel Clarke presents findings from the STAMPEDE trial regarding fracture risk and bone protection in prostate cancer patients. The presentation demonstrates that zoledronic acid reduces fracture incidence by about 50% in metastatic disease, and treatment intensification with abiraterone shows substantial fracture risk reduction, wh...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Joaquin Mateo discusses PARP inhibitors in BRCA-mutated prostate cancer treatment. He explores their effectiveness against tumors with impaired homologous recombination repair while highlighting key findings from PROfound and TRITON3 trials. Biographies: Joaquin Mateo, MD, PhD, Medical Oncologist, Prostate Cancer Translational Rese...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Johann Sebastian de Bono discusses the complexities of PARP inhibition in prostate cancer treatment. The presentation highlights concerns about widespread PARP inhibitor use without proper patient selection and raises awareness about potential long-term risks, while emphasizing the need for improved testing methods and careful cons...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Elena Castro provides a comprehensive overview of PARP inhibitor safety profiles in prostate cancer treatment. The presentation outlines specific management strategies while addressing the rare risk of myelodysplastic syndrome and acute myeloid leukemia, concluding that for patients with BRCA or HRR alterations, the benefits outwei...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
